Yinjia Biotechnology

What Yinjia Biotechnology does

Yinjia Biotechnology (引加(上海)生物医药科技有限公司) is a privately held protein technology platform founded in November 2020 and headquartered in Shanghai, with additional R&D and manufacturing facilities in Suzhou (GMP) and Beijing. The company develops and commercializes high-end protein raw materials — antigens, antibodies, enzymes, cytokines, and related reagents — benchmarked against international first-tier brands, alongside a portfolio of quality control and safety evaluation kits for therapeutic biologics manufacturing (residual detection kits for Protein A, trypsin, AAV8, and adenovirus titer, among others). Its underlying technology combines an AI-assisted protein design stack (generative AI plus computational simulation) with a proprietary cell-free protein synthesis (CFPS) E.coli platform capable of expressing proteins up to 130 kDa within 16 hours, enabling rapid development of difficult-to-express proteins. The company also offers custom protein expression services spanning prokaryotic, yeast, insect, and mammalian cell systems, with scale-up to GMP-grade production.

The company serves four primary customer segments: listed pharmaceutical and innovative biotech firms (for ADC, antibody, and new drug development); listed and emerging IVD diagnostics companies (for core diagnostic antigens and enzymes); cell and gene therapy firms (for raw materials and QC kits); and academic and research institutes. Customer logos named in the data include listed pharma, innovative biotech, listed diagnostics firms, and institutions such as Shanghai Jiao Tong University School of Medicine. The go-to-market is predominantly direct B2B sales, supplemented by a 2022 dual-brand distribution partnership with Quanxin Quanyi's cloud supply chain platform. Approximately 200 SKUs have been launched across eight product categories, including ADC enzymatic conjugation tools, mass-spectrometry-grade recombinant trypsin, PNGase F, molecular enzymes for qPCR/RT-qPCR, and rapid antibody labeling kits.

Yinjia has completed three funding rounds totaling over 100M RMB: an angel round in early 2021 led by CDH Investments with Furong Investment, a Pre-A round in July 2021 led by Gaorong Capital with CDH VGC and Furong Investment, and a Series A in January 2023 led by CMB International with Suzhou Xinhe Guoqing Fund. The company holds ISO 9001:2015 and ISO 13485:2016 certifications, EU CE marking for Suzhou manufacturing, and has received national high-tech enterprise, Shanghai 'specialized and innovative SME,' and technology-based SME designations, in addition to multiple industry awards from CHC-CITIC Securities. Active strategic partnerships include Bo Teng Bio (CGT raw materials), Xin Yuan Bio (lung cancer detection proteins), Miao Shun Bio (CGT upstream cell resources), and academic collaborations with Shanghai Jiao Tong University. The most recent strategic moves — partnerships with BaiAo Geometry (May 2024) and Cheng Kong Shu Xin (May 2026) — signal an explicit buildout toward a closed-loop AI-protein design and synthesis platform.

Name

Yinjia Biotechnology

Legal name

引加(上海)生物医药科技有限公司

Website

https://yinjiabio.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Yinjia Biotechnology is a Shanghai-based protein technology platform founded in 2020 that develops and sells ~200 high-end protein raw materials and biologics QC kits to pharma, biotech, IVD, and CGT firms in China, using an AI-assisted protein design and proprietary cell-free protein synthesis (CFPS) platform.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

akta.pro secondary industries

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)

Keywords

• Recombinant protein reagents
• Cell-free protein synthesis
• Biologics quality control
• IVD diagnostic raw materials
• ADC drug development enzymes

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. High-end Protein Reagents and Raw Materials: Revenue primarily from sale of high-end protein raw materials (antigens, antibodies, enzymes) and custom protein development services. Products are sold as catalog reagents and custom orders to pharmaceutical companies, biotech firms, and research institutes. Multiple expression systems offered (prokaryotic, yeast, insect, mammalian).
2. Quality Control and Detection Reagent Kits: Sale of detection and quality control kits for therapeutic biologics manufacturing, including residual detection kits (Protein A, trypsin), viral titer assay kits, and other QC products for biopharmaceutical production.
3. Custom Protein Development Services: Provides custom protein expression and development services using multiple platforms (prokaryotic, yeast, insect, mammalian cell systems). Services range from gene synthesis to protein expression, fermentation, purification, formulation, and quality testing. Includes R&D (mg), pilot (g), scale-up production (1000g), and GMP-level manufacturing.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Yinjia Biotechnology develops and sells high-end recombinant protein raw materials, enzymes, and detection kits for the biopharmaceutical and IVD industries. The company operates an AI-driven cell-free protein synthesis (CFPS) platform to produce nearly 200 catalog protein reagents spanning ADC enzymes (Sortase A, Endo S2, mTGase), protein analysis enzymes (mass spectrometry-grade trypsin, PNGase F), QC residual detection kits (Protein A, AAV8 titer), molecular enzymes (qPCR/RT-qPCR), and cytokines/target proteins. It also provides custom protein development services across multiple expression systems with GMP manufacturing capabilities in Suzhou.

Product overview

Yinjia Biotechnology is a technology platform company offering a comprehensive portfolio of high-end protein products and services. The core offerings span eight main categories: (1) AI-enabled protein prediction platforms including the CFPS E.coli cell-free protein expression system for high-throughput AI protein design validation; (2) ADC drug development enzymes including mTGase, Sortase A, Endo S2, B4GALT1 variants, and β-1,4-N-acetylgalactosaminyltransferase; (3) Protein/antibody analysis enzymes including recombinant trypsin (mass spectrometry grade), PNGase F, Glu-C protease, Lys-C endopeptidase, and various protease kits; (4) Residue/QC detection kits including Protein A, trypsin, AAV8, and adenovirus titer detection kits; (5) Cell/organoid products including recombinant trypsin digestion solutions, tissue digestion kits, IGF-1 analogs, and growth factors (VEGF165, bFGF); (6) Molecular enzymes for qPCR, RT-qPCR, isothermal amplification, and RNA vaccine applications including various DNA/RNA polymerases, ligases, nucleases, and capping enzymes; (7) Diagnostic/cytokine/target proteins including Tau proteins, TNFα, interleukins, interferons, and kinases; (8) Protein/antibody rapid labeling reagents including HRP, ALP, FITC, and Biotin conjugation kits. The company provides custom protein expression services across multiple expression systems (prokaryotic, yeast, insect, mammalian) and supports drug discovery, diagnostics, vaccines, and cell therapy applications.

Differentiator

Problem solved

Functional benefit

Brands

• 泉品: 与泉心泉意合作推出的双品牌蛋白产品系列

Products and services

• CFPS E.coli Cell-Free Protein Expression System (CFPS E.coli 无细胞蛋白表达系统)

Quantifiable outcome

• 开发出近200种高端蛋白原料，性能对标国际一流品牌
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and major.

• 杭州程控数芯生物科技有限公司 (Cheng Kong Shu Xin)coreStrategic or Co-development Partner · 8 May 2026Strategic cooperation signed in 2026 to build an industry-leading dry-wet closed-loop high-end protein design and synthesis paradigm. Combining Yinjia's cell-free protein synthesis with Cheng Kong Shu Xin's Turing programmable AI biological chip lab (digital microfluidic chip technology) for automated high-throughput protein expression verification, significantly shortening the AI protein design-validation cycle.
• 北京百奥几何生物科技有限公司 (BaiAo Geometry)coreStrategic or Co-development Partner · 31 May 2024Strategic cooperation signed on May 31, 2024, combining BaiAo Geometry's leading generative AI protein design technology with Yinjia's experience in complex protein process development and scale-up manufacturing. The goal is to develop more source-innovative and scarce high-end protein raw materials and extended products, advancing breakthroughs in biopharmaceutical and other major livelihood areas.
• 芯原生物科技有限公司 (Xin Yuan Bio)majorStrategic or Co-development Partner · 17 January 2024Strategic cooperation signed Jan 17, 2024 for deep collaboration in protein raw material development for Xin Yuan Bio's innovative detection products. Yinjia provides eukaryotic-expressed protein raw materials to address domestic gaps in key protein ingredients for lung cancer detection products.
• 妙顺(上海)生物科技有限公司 (Miao Shun Bio)majorStrategic or Co-development Partner · 30 August 2023Strategic cooperation signed Aug 30, 2023 to combine Yinjia's protein and detection technology platform with Miao Shun Bio's upstream cell resources in the cell and gene therapy field, providing more product and service options for Chinese biomedical enterprises.
• 苏州博腾生物制药有限公司 (Bo Teng Bio)coreStrategic or Co-development Partner · 20 February 2023Strategic partnership announced Feb 20, 2023, focusing on development of core protein raw materials for cell and gene therapy and quality control assay kits. Yinjia provides high-quality core protein raw materials and QC reagent products to support Bo Teng Bio's CGT CDMO platform capabilities.
• 泉心泉意(上海)生命科技有限公司 (Quanxin Quanyi)majorChannel Partner/ Reseller/ Distributor · 11 July 2022Dual-brand strategic cooperation ('引加×泉品') leveraging Quanxin Quanyi's cloud wisdom supply chain platform covering full lifecycle of biomedicine from R&D to production, enabling precise customer targeting through their digital SaaS procurement platform.
• 上海上药康希诺生物制药有限公司 (Shangpharma-CanSino Biologics)majorStrategic or Co-development Partner · 15 June 2022Cooperation agreement signed June 2022 for joint development of protein products and efficacy/safety assay kits for Shangpharma-CanSino's biological drug production, and collaboration on other complementary projects.
• 上海智峪生物科技有限公司 (Zhi Yu Sheng Ke)coreStrategic or Co-development Partner · 6 May 2022Strategic cooperation combining Zhi Yu Sheng Ke's AI protein structure prediction technology (ZCloud platform) with Yinjia's protein design, process development and large-scale production experience, forming a comprehensive protein optimization platform for difficult and de novo protein R&D.
• 上海交通大学医学院上海市免疫学研究所 (Shanghai Jiao Tong University School of Medicine - Shanghai Institute of Immunology)majorStrategic or Co-development Partner · 7 March 2022Cooperation agreement signed for collaboration in immunology research and protein development.
• IsoPlexis (USA)majorStrategic or Co-development Partner · 4 August 2021Strategic cooperation framework to promote IsoPlexis's single-cell multi-omics analysis platform (IsoCode chip technology) for real-time dynamic monitoring of patient response to tumor immunotherapy and cell therapy efficacy/toxicity. Joint lab established in Shanghai.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• ACROBiosystems: ACROBiosystems is a Chinese biopharmaceutical company specializing in recombinant proteins, antibodies, and other critical reagents for drug development, diagnostics, and research. It is the most direct competitor to Yinjia in the Chinese protein reagents market, with comparable product breadth across antigens, enzymes, and QC reagents.
• Sino Biological: Sino Biological is a leading Chinese reagent provider offering recombinant proteins, antibodies, and related services for biopharmaceutical and diagnostic applications. It directly competes with Yinjia in the high-end protein reagents space, particularly for IVD and biologics manufacturing customers.
• GenScript ProBio: GenScript ProBio provides protein and gene synthesis services, recombinant protein production, and antibody development. It is a direct competitor to Yinjia's custom protein services and recombinant protein offerings, particularly serving Chinese biopharma and biotech customers.

Emerging players

• Novoprotein Scientific: Novoprotein is a Chinese recombinant protein company offering cytokines, growth factors, and custom protein services for research and diagnostics. It overlaps with Yinjia's cell therapy and diagnostic protein offerings, particularly as an emerging alternative for research-grade reagents.
• Kactus Biosystems: Kactus Biosystems is a Chinese biotech company specializing in cell-free protein synthesis and recombinant protein production. It shares Yinjia's CFPS technology focus and competes in the difficult-to-express protein niche.

Broad incumbents

• Bio-Techne: Bio-Techne (including R&D Systems, Novus Biologicals, ProteinSimple) is a global leader in protein reagents, with deep catalogs in cytokines, antibodies, and assay kits. It represents the global incumbent that Yinjia explicitly benchmarks against, with broader scale and established brand equity.
• Thermo Fisher Scientific: Thermo Fisher Scientific is the global leader in life science tools, offering protein reagents, antibodies, and biopharma services through brands like Gibco, Invitrogen, and Patheon. It is the dominant incumbent Yinjia competes against, with unmatched scale, distribution, and integrated solutions.
• Cytiva (Danaher): Cytiva, part of Danaher, provides bioprocessing and life science tools including protein purification, cell culture media, and analytical instruments. It overlaps with Yinjia's bioprocessing and QC product lines, particularly for biologics manufacturers.
• WuXi AppTec: WuXi AppTec is a global CRO/CDMO providing integrated R&D and manufacturing services to biopharma. It is also the former employer of Yinjia's founder and represents a broad incumbent in protein-related services, though not a direct catalog competitor.
• DiaSorin: DiaSorin is a global diagnostics company providing IVD reagents and specialty proteins. It represents an established incumbent in the IVD raw materials space where Yinjia supplies antigens, antibodies, and enzymes.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yinjia Biotechnology